JP2010534237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534237A5 JP2010534237A5 JP2010517507A JP2010517507A JP2010534237A5 JP 2010534237 A5 JP2010534237 A5 JP 2010534237A5 JP 2010517507 A JP2010517507 A JP 2010517507A JP 2010517507 A JP2010517507 A JP 2010517507A JP 2010534237 A5 JP2010534237 A5 JP 2010534237A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- lcdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 176
- 102000016359 Fibronectins Human genes 0.000 claims 7
- 108010067306 Fibronectins Proteins 0.000 claims 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- 102000001708 Protein Isoforms Human genes 0.000 claims 5
- 108010029485 Protein Isoforms Proteins 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 239000012502 diagnostic product Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95176507P | 2007-07-25 | 2007-07-25 | |
| US60/951,765 | 2007-07-25 | ||
| PCT/IB2008/002536 WO2009013619A2 (en) | 2007-07-25 | 2008-07-24 | The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013026422A Division JP5705893B2 (ja) | 2007-07-25 | 2013-02-14 | 腫瘍転移の新生血管と関連するフィブリノーゲンのｅｄ−ａ抗原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534237A JP2010534237A (ja) | 2010-11-04 |
| JP2010534237A5 true JP2010534237A5 (OSRAM) | 2012-10-04 |
| JP5204228B2 JP5204228B2 (ja) | 2013-06-05 |
Family
ID=40085445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517507A Expired - Fee Related JP5204228B2 (ja) | 2007-07-25 | 2008-07-24 | 腫瘍転移の新生血管と関連するフィブリノーゲンのｅｄ−ａ抗原 |
| JP2013026422A Expired - Fee Related JP5705893B2 (ja) | 2007-07-25 | 2013-02-14 | 腫瘍転移の新生血管と関連するフィブリノーゲンのｅｄ−ａ抗原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013026422A Expired - Fee Related JP5705893B2 (ja) | 2007-07-25 | 2013-02-14 | 腫瘍転移の新生血管と関連するフィブリノーゲンのｅｄ−ａ抗原 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20100183506A1 (OSRAM) |
| EP (2) | EP2167541B1 (OSRAM) |
| JP (2) | JP5204228B2 (OSRAM) |
| KR (1) | KR101781638B1 (OSRAM) |
| CN (2) | CN101754978B (OSRAM) |
| AU (2) | AU2008278702B2 (OSRAM) |
| BR (1) | BRPI0812765B8 (OSRAM) |
| CA (1) | CA2691218C (OSRAM) |
| EA (1) | EA017995B1 (OSRAM) |
| ES (2) | ES2398536T3 (OSRAM) |
| WO (1) | WO2009013619A2 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA036322B1 (ru) | 2007-04-02 | 2020-10-26 | Филоджен С.П.А. | Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов |
| PT3281952T (pt) | 2007-10-30 | 2020-07-23 | Philogen Spa | Um antigénio associado a artrite reumatoide |
| US9527907B2 (en) | 2009-01-07 | 2016-12-27 | Philogen S.P.A. | Antigens associated with endometriosis, psoriatic arthritis and psoriasis |
| ES2712997T3 (es) * | 2009-08-05 | 2019-05-17 | Philogen Spa | Selección como diana de neovasculatura de médula ósea |
| EP2632950B1 (en) * | 2010-10-26 | 2018-08-22 | UMC Utrecht Holding B.V. | Antibody binding to fibronectin-eda for preventing myocardial infarction-related complications |
| US9580485B2 (en) * | 2011-07-27 | 2017-02-28 | Philogen S.P.A. | IL-12 immunoconjugate |
| SI2903629T1 (sl) | 2012-10-03 | 2019-09-30 | Philogen S.P.A. | Konjugat protitelesa za uporabo pri zdravljenju vnetnih črevesnih bolezni |
| US10011652B2 (en) | 2013-12-12 | 2018-07-03 | Umc Utrecht Holding B.V. | Immunoglobulin-like molecules directed against fibronectin-EDA |
| MX2017007663A (es) * | 2014-12-12 | 2018-03-15 | Encare Biotech B V | Moleculas tipo inmunoglobulina dirigidas contra fibronectina eda. |
| ES2778430T3 (es) | 2015-07-16 | 2020-08-10 | Philogen Spa | Inmunoconjugados de IL22 |
| KR102338660B1 (ko) | 2016-10-17 | 2021-12-10 | 화이자 인코포레이티드 | 항-edb 항체 및 항체-약물 접합체 |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| CN110997718B (zh) | 2017-06-07 | 2023-11-10 | 菲洛根股份公司 | 血管内皮生长因子/抗纤连蛋白抗体融合蛋白 |
| PL237087B1 (pl) | 2017-10-25 | 2021-03-08 | Univ Medyczny Im Piastow Slaskich We Wroclawiu | Sposób diagnozowania nowotworów układu chłonnego |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| US20230285585A1 (en) | 2020-07-22 | 2023-09-14 | Philogen S.P.A. | Treatment of pulmonary hypertension |
| US20250197485A1 (en) | 2022-03-17 | 2025-06-19 | Universitätsklinikum Jena | Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5420012A (en) * | 1989-05-08 | 1995-05-30 | Locus Genex Oy | Method for the detection of reactive conditions |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5644033A (en) * | 1992-12-22 | 1997-07-01 | Health Research, Inc. | Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment |
| ATE439592T1 (de) | 1998-12-10 | 2009-08-15 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| ATE333900T1 (de) | 2000-02-24 | 2006-08-15 | Philogen Spa | Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
| WO2001076630A1 (en) * | 2000-04-06 | 2001-10-18 | Kyowa Hakko Kogyo Co., Ltd. | Diagnostics and remedies for rheumatoid arthritis |
| IT1317108B1 (it) | 2000-12-06 | 2003-05-26 | Philogen Srl | Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso. |
| EP1224943A1 (en) * | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
| CA2523452A1 (en) * | 2003-04-22 | 2004-11-04 | A & G Pharmaceutical, Inc. | Cancer specific monoclonal antibodies |
| CA2575675A1 (en) * | 2004-07-30 | 2006-03-09 | Adeza Biomedical Corporation | Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin |
| US7785591B2 (en) * | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| EA036322B1 (ru) * | 2007-04-02 | 2020-10-26 | Филоджен С.П.А. | Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов |
| ES2712997T3 (es) * | 2009-08-05 | 2019-05-17 | Philogen Spa | Selección como diana de neovasculatura de médula ósea |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2008
- 2008-07-24 ES ES08807180T patent/ES2398536T3/es active Active
- 2008-07-24 EP EP08807180A patent/EP2167541B1/en active Active
- 2008-07-24 JP JP2010517507A patent/JP5204228B2/ja not_active Expired - Fee Related
- 2008-07-24 CA CA2691218A patent/CA2691218C/en active Active
- 2008-07-24 US US12/665,930 patent/US20100183506A1/en not_active Abandoned
- 2008-07-24 EP EP12195313.7A patent/EP2612869B1/en active Active
- 2008-07-24 ES ES12195313.7T patent/ES2534726T3/es active Active
- 2008-07-24 WO PCT/IB2008/002536 patent/WO2009013619A2/en not_active Ceased
- 2008-07-24 CN CN2008800252537A patent/CN101754978B/zh not_active Expired - Fee Related
- 2008-07-24 KR KR1020107004009A patent/KR101781638B1/ko not_active Expired - Fee Related
- 2008-07-24 BR BRPI0812765A patent/BRPI0812765B8/pt not_active IP Right Cessation
- 2008-07-24 CN CN201310127909.9A patent/CN103212072B/zh not_active Expired - Fee Related
- 2008-07-24 EA EA201070179A patent/EA017995B1/ru not_active IP Right Cessation
- 2008-07-24 AU AU2008278702A patent/AU2008278702B2/en not_active Ceased
-
2013
- 2013-02-14 JP JP2013026422A patent/JP5705893B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-02 AU AU2014203612A patent/AU2014203612B2/en not_active Ceased
- 2014-08-11 US US14/456,966 patent/US20150030536A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534237A5 (OSRAM) | ||
| JP2010523541A5 (OSRAM) | ||
| RU2010121874A (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| JP2011502137A5 (OSRAM) | ||
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| JP2013121353A5 (OSRAM) | ||
| RU2017145653A (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| JP2017530092A5 (OSRAM) | ||
| JP2017526339A5 (OSRAM) | ||
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| CY1120014T1 (el) | Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες | |
| JP2014511179A5 (OSRAM) | ||
| HRP20211125T1 (hr) | Konjugati protutijelo-lijek koji se temelje na eribulinu i postupci uporabe | |
| JP2011501656A5 (OSRAM) | ||
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| JP2017519501A5 (OSRAM) | ||
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| BRPI0712953B8 (pt) | anticorpos anti-nkg2a, seu uso, e composição farmacêutica | |
| JP2018529634A5 (OSRAM) | ||
| JP2013542194A5 (OSRAM) | ||
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| NZ598391A (en) | Anti-hepcidin antibodies and uses thereof | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2016512832A5 (OSRAM) | ||
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. |